Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Hum Psychopharmacol 2009; 24(6):447-52HP

Abstract

OBJECTIVE

To investigate the efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.

METHOD

Thirty-nine patients fulfilling DSM-IV-TR diagnostic criteria for schizophrenia and had depressive symptoms were studied in a prospective 6-week open-label design using quetiapine monotherapy. The brief psychiatric rating scale (BPRS), 17-item Hamilton depression rating scale (HAMD-17), Simpson-Angus rating scale, and the Barnes Akathisia rating scale (BARS) were used to assess patients at baseline, week 1, 2, 4, and 6.

RESULTS

Thirty patients (76.9%) completed this study. The dose of quetiapine at endpoint was 583 (+/-235 SD) mg/day. Treatment with Quetiapine was associated with significantly reduced depressive symptoms (HAMD-17 total score and BPRS depression/anxiety subscale) from the first week of treatment. Changes of mean score from baseline to endpoint were 7.8 +/- 6.2 for HAMD-17 total score and 3.4 +/- 3.6 for BPRS depression/anxiety subscale (LOCF, n = 39, p < 0.001). Quetiapine was well tolerated, with minimal extrapyramidal symptoms and non-significant increase in body weight (mean increase of 0.8 kg).

CONCLUSIONS

While the interpretation of findings from the open-label design of this study warrants appropriate caution, the results suggest that quetiapine may be an effective and tolerable treatment for depression in patients with schizophrenia.

Authors+Show Affiliations

Department of Psychiatry, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Korea.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19606454

Citation

Lee, Kyoung-Uk, et al. "Efficacy and Safety of Quetiapine for Depressive Symptoms in Patients With Schizophrenia." Human Psychopharmacology, vol. 24, no. 6, 2009, pp. 447-52.
Lee KU, Jeon YW, Lee HK, et al. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Hum Psychopharmacol. 2009;24(6):447-52.
Lee, K. U., Jeon, Y. W., Lee, H. K., & Jun, T. Y. (2009). Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Human Psychopharmacology, 24(6), pp. 447-52. doi:10.1002/hup.1047.
Lee KU, et al. Efficacy and Safety of Quetiapine for Depressive Symptoms in Patients With Schizophrenia. Hum Psychopharmacol. 2009;24(6):447-52. PubMed PMID: 19606454.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. AU - Lee,Kyoung-Uk, AU - Jeon,Yang-Whan, AU - Lee,Hae-Kook, AU - Jun,Tae-Youn, PY - 2009/7/17/entrez PY - 2009/7/17/pubmed PY - 2009/10/21/medline SP - 447 EP - 52 JF - Human psychopharmacology JO - Hum Psychopharmacol VL - 24 IS - 6 N2 - OBJECTIVE: To investigate the efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. METHOD: Thirty-nine patients fulfilling DSM-IV-TR diagnostic criteria for schizophrenia and had depressive symptoms were studied in a prospective 6-week open-label design using quetiapine monotherapy. The brief psychiatric rating scale (BPRS), 17-item Hamilton depression rating scale (HAMD-17), Simpson-Angus rating scale, and the Barnes Akathisia rating scale (BARS) were used to assess patients at baseline, week 1, 2, 4, and 6. RESULTS: Thirty patients (76.9%) completed this study. The dose of quetiapine at endpoint was 583 (+/-235 SD) mg/day. Treatment with Quetiapine was associated with significantly reduced depressive symptoms (HAMD-17 total score and BPRS depression/anxiety subscale) from the first week of treatment. Changes of mean score from baseline to endpoint were 7.8 +/- 6.2 for HAMD-17 total score and 3.4 +/- 3.6 for BPRS depression/anxiety subscale (LOCF, n = 39, p < 0.001). Quetiapine was well tolerated, with minimal extrapyramidal symptoms and non-significant increase in body weight (mean increase of 0.8 kg). CONCLUSIONS: While the interpretation of findings from the open-label design of this study warrants appropriate caution, the results suggest that quetiapine may be an effective and tolerable treatment for depression in patients with schizophrenia. SN - 1099-1077 UR - https://www.unboundmedicine.com/medline/citation/19606454/Efficacy_and_safety_of_quetiapine_for_depressive_symptoms_in_patients_with_schizophrenia_ L2 - https://doi.org/10.1002/hup.1047 DB - PRIME DP - Unbound Medicine ER -